subunit influenza vaccine
Vaccineexperimental
Clinical trial activity
13 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
8
Phase 3
7
Phase 4
1
Earliest trial started Sep 1, 2004 (NCT00492063)
Timeline
Indications
Approved for
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cell culture-derived influenza subunit vaccine
- subunit, inactivated, influenza vaccine
- subunit influenza vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03816878 | Phase 1 | Jan 8, 2019 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01640314 | Phase 3 | Jul 1, 2012 | Novartis |
| NCT01342796 | Phase 2 | Apr 1, 2011 | Novartis |
| NCT00889889 | Phase 2 | May 1, 2009 | Abbott, IQVIA |
| NCT00560066 | Phase 4 | Nov 1, 2007 | Novartis |
| NCT00579345 | Phase 3 | Oct 1, 2007 | Novartis |
| NCT00559975 | Phase 1 | Oct 1, 2007 | Novartis |
| NCT00630331 | Phase 3 | Oct 1, 2007 | Novartis |
| NCT00645411 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2007 | Novartis |
| NCT00336635 | Phase 1 | Jun 1, 2006 | CJ HealthCare Corp., Seoul National University |
| NCT00306527 | Phase 3 | Sep 1, 2005 | Novartis |
| NCT00310804 | Phase 3 | Sep 1, 2005 | Novartis |
| NCT00492063 | Phase 3 | Sep 1, 2004 | Novartis |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 10 | 10 | 4 | 2004 |
| Abbott | For profit | 1 | 1 | 1 | 2009 |
| CJ HealthCare Corp. | For profit | 1 | 0 | 1 | 2006 |
| IQVIA | For profit | 1 | 0 | 1 | 2009 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2019 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2006 |
7 organizations
Page 1 / 1